Welcome to our dedicated page for Artelo Biosciences news (Ticker: $ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Artelo Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Artelo Biosciences's position in the market.
Rhea-AI Summary
Artelo Biosciences announces the publication of a peer-reviewed article highlighting FABP7 as a promising novel target in cancer therapy. The article discusses the role of FABP7 in various cancers, its potential as a validated target in cancer treatment, and the impact of FABP7 inhibition on tumor growth and patient prognosis. Artelo is focused on developing FABP inhibitors for cancer and other serious conditions, with the lead compound ART26.12 showing promising results in preclinical studies for conditions like cancer bone pain and chemotherapy-induced peripheral neuropathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
-
Rhea-AI Summary
Artelo Biosciences CEO, Gregory D. Gorgas, will be a guest on Benzinga All Access on April 23rd at 10:50 AM Eastern Time. Artelo focuses on developing treatments for cancer, pain, dermatologic, and neurological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
-
Rhea-AI Summary
Artelo Biosciences, Inc. reports significant achievements in 2023, focusing on key milestones in cancer treatment development. The company completed phase 1b and initiated phase 2a of the Cancer Appetite Recovery Study (CAReS) with ART27.13, advanced ART 26.12 toward IND submission for neuropathic pain treatment, and presented data on the efficacy of ART12.11 in anxiety and depression models. The company also highlighted safety results for ART27.13, published research on its protective properties, and announced positive effects of ART26.12 in neuropathic pain models. Financially, Artelo Biosciences ended 2023 with $10.4 million in cash and investments, with R&D expenses at $5.7 million and a net loss of $9.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
Rhea-AI Summary
Artelo Biosciences, Inc. (ARTL) presents preclinical dermatology research on ART26.12 to Johnson & Johnson's Innovation Challenge, showcasing potential in treating dermatological conditions beyond cancer and pain. The FABP5 inhibitor, ART26.12, demonstrates positive effects in preclinical psoriasis models, offering promise for future clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
-
Rhea-AI Summary
Artelo Biosciences, Inc. (ARTL) will participate in the Winter Wrap-Up MicroCap Rodeo Conference to present their lipid-signaling pathways treatments for cancer, pain, and neurological conditions. CEO Gregory D. Gorgas will present on February 20th and meet with investors on February 22nd and 23rd.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
-
Rhea-AI Summary
Artelo Biosciences, Inc. (ARTL) announced new research published in the peer-reviewed Journal of Pain, highlighting its pre-clinical asset, ART26.12, and its potential ability to treat and prevent Oxaliplatin-Induced Peripheral Neuropathy. The global neuropathic pain market is estimated at $7.6 billion, demonstrating the need for innovative therapy. Artelo has conducted multiple pre-clinical studies in painful neuropathies and anticipates filing the IND for ART26.12 in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
Rhea-AI Summary
Artelo Biosciences, a clinical-stage pharmaceutical company (Nasdaq: ARTL), has selected Worldwide Clinical Trials to support its Phase 1 trial with ART26.12, a FABP5 inhibitor for chemotherapy-induced peripheral neuropathy. The global neuropathic pain market is valued at $7.6 billion, showing the need for innovative therapies. Artelo anticipates filing the IND for ART26.12 in the first half of this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
-
Rhea-AI Summary
Artelo Biosciences, Inc. (Nasdaq: ARTL) announced new preclinical data on ART12.11, a proprietary cocrystal of cannabidiol (CBD) and tetramethylpyrazine (TMP), demonstrating improved CBD bioavailability and efficacy in both the fed and fasted states compared to CBD alone. The presentation at the 4th Annual Med-Cannabis 2023 conference discussed greater anxiolytic, anti-depressive, and pro-social effects of ART12.11 compared to CBD alone, highlighting its potential therapeutic utility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
-
Rhea-AI Summary
Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that George Warren, PhD., will present new preclinical data on ART12.11, a proprietary cocrystal of cannabidiol (CBD) and tetremethylpyrazine (TMP), at the 4th Annual Med-Cannabis 2023 conference in Frankfurt, Germany.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
Rhea-AI Summary
Artelo Biosciences, Inc. (Nasdaq: ARTL) Reports $12.9 Million in Cash and Investments as of September 30, 2023; On Track to Submit IND Application with the FDA for ART26.12 in 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Artelo Biosciences, Inc.
Nasdaq:ARTL
ARTL Rankings
ARTL Stock Data
4.16M
3.20M
0.83%
0.78%
0.45%
Tobacco Manufacturing
Manufacturing
United States of America
SOLANA BEACH
About ARTL
artelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. our programs have the potential to dramatically improve patient care in major markets. with our headquarters team in san diego, california, usa and our european office in dublin, ireland, artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in europe and north america.